SCHEMBL4713568

SCHEMBL4713568

[CH2]NC(C)C(O)c1ccc(O)cc1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ADRA1A P35348 6/20 0.54
▸ HIF1A Q16665 5/20 0.54
▸ SLC6A2 P23975 5/20 0.54
▸ OPRM1 P35372 5/20 0.54
▸ CYP2D6 P10635 5/20 0.54
▸ LMNA P02545 4/20 0.54
▸ SLC6A3 Q01959 4/20 0.54
▸ ADRB2 P07550 3/20 0.54
▸ SLC6A4 P31645 3/20 0.54
▸ ADRB1 P08588 2/20 0.54
▸ OPRK1 P41145 2/20 0.54
▸ GALR3 O60755 1/20 0.54
▸ ADRB3 P13945 1/20 0.53
▸ TMEM97 Q5BJF2 1/20 0.53
▸ SIGMAR1 Q99720 1/20 0.53
▸ ESR1 P03372 2/20 0.48
▸ PDCD1 Q15116 1/20 0.48
▸ ESR2 Q92731 1/20 0.48
▸ CD274 Q9NZQ7 1/20 0.48
▸ CYP2C19 P33261 4/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Oxilofrine SCHEMBL147458 0.81 ADRA1A (0.67) ADRA1AHIF1ASLC6A2OPRM1CYP2D6
SCHEMBL20690347 0.81 HIF1A (0.56) ADRA1AHIF1ASLC6A2OPRM1CYP2D6
SCHEMBL28340700 0.81 ADRA2C (0.67) ADRA1AHIF1ACYP2D6LMNASLC6A4
Oxilofrine SCHEMBL4256893 0.81 ADRA1A (0.67) ADRA1AHIF1ASLC6A2OPRM1CYP2D6
Oxilofrine SCHEMBL14153976 0.81 ADRA1A (0.67) ADRA1AHIF1ASLC6A2OPRM1CYP2D6
Oxilofrine SCHEMBL5173040 0.81 ADRA1A (0.67) ADRA1AHIF1ASLC6A2OPRM1CYP2D6
Oxilofrine SCHEMBL14465574 0.81 ADRA1A (0.67) ADRA1AHIF1ASLC6A2OPRM1CYP2D6
SCHEMBL27623223 0.80 HIF1A (0.53) ADRA1AHIF1ASLC6A2OPRM1CYP2D6
SCHEMBL2123890 0.79 HIF1A (0.54) ADRA1AHIF1ASLC6A2OPRM1CYP2D6
SCHEMBL16144662 0.79 HIF1A (0.55) ADRA1AHIF1ASLC6A2OPRM1CYP2D6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1887007-A2 Novel compounds AstraZeneca AB (SE) 2008-02-13 — — EP claimed
EP-1625126-B1 IMIDAZO AND THIAZOLOPYRIDINES AS JAK3 KINASE INHIBITORS ASTRAZENECA AB (SE) 2008-01-16 — — EP claimed
US-20060287355-A1 Imidazo and thiazolopyridines as jak3 kinase inhibitors ASTRAZENECA AB (SE) 2006-12-21 — — US claimed
EP-1887007-A2 Novel compounds AstraZeneca AB (SE) 2008-02-13 — — EP disclosed
EP-1625126-B1 IMIDAZO AND THIAZOLOPYRIDINES AS JAK3 KINASE INHIBITORS ASTRAZENECA AB (SE) 2008-01-16 — — EP disclosed
US-20060287355-A1 Imidazo and thiazolopyridines as jak3 kinase inhibitors ASTRAZENECA AB (SE) 2006-12-21 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060287355-A1 Imidazo and thiazolopyridines as jak3 kinase inhibitors JAK3, JAK2, JAK1 ADRA1A 2780/4885HIF1A 2395/4885SLC6A2 4806/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback